Difference between revisions of "Maprotiline-dosulepine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = maprotiline | to = dosulepine | stop = * Gradually reduce dosage of maprotiline to a maximum of 25-75 mg/day. * When a dosage of 25-75 mg/day is reached,...')
 
Line 7: Line 7:
 
| start =  
 
| start =  
 
* No wash-out period is needed.  
 
* No wash-out period is needed.  
* Start administration of dosulepine the next day in a normal dosage of 50-75 mg/day.}}
+
* Start administration of dosulepine the next day in a normal dosage of 50-75 mg/day.
 +
|info=
 +
{{review}}
 +
 
 +
}}

Revision as of 13:48, 2 November 2015

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin

Switch medication from maprotiline to dosulepine.[1] [2]

Nietinrijdenbord.png Stop maprotiline
  • Gradually reduce dosage of maprotiline to a maximum of 25-75 mg/day.
  • When a dosage of 25-75 mg/day is reached, stop administration.
Eenrichtingbord.png Start dosulepine
  • No wash-out period is needed.
  • Start administration of dosulepine the next day in a normal dosage of 50-75 mg/day.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.